Venetoclax combined with multi-frequency decitabine, vincristine and dexamethasone (VDVD) as induction therapy for patients with de novo acute leukaemia of ambiguous lineage

Abstract Acute leukaemia of ambiguous lineage (ALAL) is a rare and heterogeneous leukaemia with unsatisfactory outcomes from conventional chemotherapy. Venetoclax (VEN) has shown potential efficacy in ALAL. Our pilot study demonstrated that VEN combined with multi-frequency decitabine (DEC) was safe and effective in elderly acute myeloid leukaemia (AML) patients. We therefore designed VDVD regimen (VEN, multi-frequency DEC, vincristine, dexamethasone) as induction therapy for de novo ALAL. VDVD comprised VEN (100 mg d1, 200 mg d2, 400 mg d3-11), DEC (20 mg/m² every 8 hours d4-6), vincristine (2 mg/d d1,8), and dexamethasone (10 mg/m² d1-4,8–11). Dasatinib was added for BCR::ABL1-positive patients. Hematopoietic stem cell transplantation (HSCT) was recommended upon achieving complete remission (CR) or complete remission with incomplete hematologic recovery (CRi). The primary endpoint was overall response rate (ORR); secondary endpoints included overall survival (OS), event-free survival (EFS) and disease-free survival (DFS). This multicenter retrospective study included 19 patients with de novo ALAL (median age 58 years, range 15–71) from 8 hospitals in China, all of whom were treated with the VDVD regimen.After one induction cycle, ORR(CR + morphologic leukaemia-free state, MLFS + partial remission, PR) was 94.73% (18/19), with CR rate of 84.21% (16/19). No induction deaths occurred. At median follow-up of 11 months (range 2–36), 3 (15.79%) patients underwent HSCT. Median OS was 11 months (range 2–36), median EFS and DFS were both 9.5 months (range 1–31​). In conclusion, the VDVD regimen demonstrates promising efficacy and a manageable safety profile as induction therapy for de novo ALAL.

Authors

Institutions

Publication Details

Journal
Scientific Reports
Published
2026-11-14
DOI
https://doi.org/10.1038/s41598-026-79095-9
Primary Topic
Acute Myeloid Leukemia Research
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Venetoclax combined with multi-frequency decitabine, vincristine and dexamethasone (VDVD) as induction therapy for patients with de novo acute leukaemia of ambiguous lineage

Guanchen Bai, 白炎亮, 索晓慧, Junshi Zhang et al.
Scientific Reports
Acute Myeloid Leukemia Research
article

Venetoclax combined with multi-frequency decitabine, vincristine and dexamethasone (VDVD) as induction therapy for patients with de novo acute leukaemia of ambiguous lineage

Guanchen Bai, 白炎亮, 索晓慧, Junshi Zhang, Jie Liu, Ling Li, Ruixia Sun, Xinxiao Lu, Yafang Chen, Fang Zheng, Xingli Zhao, Kaiqi Liu, Yingchang Mi
article en

Abstract

Abstract Acute leukaemia of ambiguous lineage (ALAL) is a rare and heterogeneous leukaemia with unsatisfactory outcomes from conventional chemotherapy. Venetoclax (VEN) has shown potential efficacy in ALAL. Our pilot study demonstrated that VEN combined with multi-frequency decitabine (DEC) was safe and effective in elderly acute myeloid leukaemia (AML) patients. We therefore designed VDVD regimen (VEN, multi-frequency DEC, vincristine, dexamethasone) as induction therapy for de novo ALAL. VDVD comprised VEN (100 mg d1, 200 mg d2, 400 mg d3-11), DEC (20 mg/m² every 8 hours d4-6), vincristine (2 mg/d d1,8), and dexamethasone (10 mg/m² d1-4,8–11). Dasatinib was added for BCR::ABL1-positive patients. Hematopoietic stem cell transplantation (HSCT) was recommended upon achieving complete remission (CR) or complete remission with incomplete hematologic recovery (CRi). The primary endpoint was overall response rate (ORR); secondary endpoints included overall survival (OS), event-free survival (EFS) and disease-free survival (DFS). This multicenter retrospective study included 19 patients with de novo ALAL (median age 58 years, range 15–71) from 8 hospitals in China, all of whom were treated with the VDVD regimen.After one induction cycle, ORR(CR + morphologic leukaemia-free state, MLFS + partial remission, PR) was 94.73% (18/19), with CR rate of 84.21% (16/19). No induction deaths occurred. At median follow-up of 11 months (range 2–36), 3 (15.79%) patients underwent HSCT. Median OS was 11 months (range 2–36), median EFS and DFS were both 9.5 months (range 1–31​). In conclusion, the VDVD regimen demonstrates promising efficacy and a manageable safety profile as induction therapy for de novo ALAL.

Scientific Reports
Handan College (CN), Chinese Academy of Medical Sciences & Peking Union Medical College (CN), Nankai University (CN), China National Pharmaceutical Group Corporation (China) (CN), Tianjin Nankai Hospital (CN), Inner Mongolia People's Hospital (CN), Henan Provincial People's Hospital (CN), The First People's Hospital of Guiyang (CN), Institute of Hematology & Blood Diseases Hospital (CN), Taian City Central Hospital (CN), State Key Laboratory of Experimental Hematology (CN)
Acute Myeloid Leukemia Research
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon